139 related articles for article (PubMed ID: 16908891)
1. Brand-name drug companies fail to meet R&D commitments.
Kondro W
CMAJ; 2006 Aug; 175(4):344. PubMed ID: 16908891
[No Abstract] [Full Text] [Related]
2. Clinical research: outlook from industry.
Echols R
Clin Perform Qual Health Care; 1996; 4(2):113-4. PubMed ID: 10156942
[No Abstract] [Full Text] [Related]
3. Strategic options for brand-name prescription drugs when patents expire.
Mehta SC; Mehta SS
Health Mark Q; 1997; 14(3):107-14. PubMed ID: 10167309
[TBL] [Abstract][Full Text] [Related]
4. Relationships between the academic community and the pharmaceutical industry: the legislative background and its effect on spending on medical research and development.
Matthews JH
Clin Invest Med; 1996 Dec; 19(6):470-8. PubMed ID: 8959357
[TBL] [Abstract][Full Text] [Related]
5. Patentees research and development expenditure in Canada.
Li S; Tomalin A
J Pharm Pharm Sci; 2002; 5(1):5-11. PubMed ID: 12042113
[TBL] [Abstract][Full Text] [Related]
6. [Is society going to finance projects of drug companies?].
Bake B
Lakartidningen; 1999 May; 96(19):2327-8. PubMed ID: 10377674
[No Abstract] [Full Text] [Related]
7. Pharmaceutical research and development.
McKercher PL
Clin Ther; 1992; 14(5):760-4; discussion 759. PubMed ID: 1468093
[TBL] [Abstract][Full Text] [Related]
8. "NIH-money-for-drug-patent-life" proposal rejected.
Fox JL
Nat Biotechnol; 1997 Dec; 15(13):1338. PubMed ID: 9415880
[No Abstract] [Full Text] [Related]
9. Scientific harassment by pharmaceutical companies: time to stop.
Hailey D
CMAJ; 2000 Jan; 162(2):212-3. PubMed ID: 10674057
[No Abstract] [Full Text] [Related]
10. Drug price deal spells windfall for researchers.
Bosch X
Nature; 2001 Nov; 414(6860):138. PubMed ID: 11700514
[No Abstract] [Full Text] [Related]
11. [Clinical drug research in Denmark--as effective, harmless and cheap as possible].
Højgaard L
Ugeskr Laeger; 1994 Feb; 156(6):784-6. PubMed ID: 8016979
[No Abstract] [Full Text] [Related]
12. What does R&D really cost?
Huff B
GMHC Treat Issues; 2001; 15(7-8):1-7. PubMed ID: 11548507
[No Abstract] [Full Text] [Related]
13. The price of pills. Does it really take $897 million for a new therapy?
Ezzell C
Sci Am; 2003 Jul; 289(1):25. PubMed ID: 12840941
[No Abstract] [Full Text] [Related]
14. Building local research and development capacity for the prevention and cure of neglected diseases: the case of India.
Kettler HE; Modi R
Bull World Health Organ; 2001; 79(8):742-7. PubMed ID: 11545331
[TBL] [Abstract][Full Text] [Related]
15. The pharmaceutical industry--to whom is it accountable?
Hayes TA
N Engl J Med; 2000 Nov; 343(19):1416; discussion 1417. PubMed ID: 11183881
[No Abstract] [Full Text] [Related]
16. The pharmaceutical industry -- will Canada become a major research centre?
Gray C
Can Med Assoc J; 1981 Apr; 124(7):910, 914-5, 918 concl. PubMed ID: 7214290
[No Abstract] [Full Text] [Related]
17. Going for the big one.
Eisenstein RI; Resnick DS
Nat Biotechnol; 2001 Sep; 19(9):881-2. PubMed ID: 11533650
[No Abstract] [Full Text] [Related]
18. After Eastman: a boost for clinical research?
Carruthers SG
Clin Invest Med; 1986; 9(2):137-8. PubMed ID: 3731579
[No Abstract] [Full Text] [Related]
19. Pharmaceutical patent legislation: a thoughtful and balanced approach.
Erola J
Clin Invest Med; 1996 Dec; 19(6):479-81. PubMed ID: 8959358
[No Abstract] [Full Text] [Related]
20. Patent protection. Canadian drug firms boost R&D spending.
Spurgeon D
Nature; 1992 Feb; 355(6362):666. PubMed ID: 1741046
[No Abstract] [Full Text] [Related]
[Next] [New Search]
